ATE429645T1 - Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten - Google Patents

Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten

Info

Publication number
ATE429645T1
ATE429645T1 AT05811604T AT05811604T ATE429645T1 AT E429645 T1 ATE429645 T1 AT E429645T1 AT 05811604 T AT05811604 T AT 05811604T AT 05811604 T AT05811604 T AT 05811604T AT E429645 T1 ATE429645 T1 AT E429645T1
Authority
AT
Austria
Prior art keywords
neurodegenerative diseases
eph receptor
receptor inhibitors
treat neurodegenerative
inhibitors
Prior art date
Application number
AT05811604T
Other languages
English (en)
Inventor
Carsten Hopf
Gerard Drewes
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of ATE429645T1 publication Critical patent/ATE429645T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
AT05811604T 2004-11-25 2005-11-25 Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten ATE429645T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04028046A EP1662259A1 (de) 2004-11-25 2004-11-25 Verwendung von Eph Rezeptor-Inhibitoren zur Behandlung von neurodegenerativen Erkrankungen
US63059204P 2004-11-26 2004-11-26
PCT/EP2005/012649 WO2006056467A1 (en) 2004-11-25 2005-11-25 Use of eph receptor inhibitors for the treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE429645T1 true ATE429645T1 (de) 2009-05-15

Family

ID=34927535

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05811604T ATE429645T1 (de) 2004-11-25 2005-11-25 Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten

Country Status (6)

Country Link
US (1) US20080213250A1 (de)
EP (2) EP1662259A1 (de)
AT (1) ATE429645T1 (de)
CA (1) CA2589173A1 (de)
DE (1) DE602005014134D1 (de)
WO (1) WO2006056467A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888648A2 (de) * 2005-06-03 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Verfahren zur behandlung, zur diagnose bzw. zum nachweis von krebs
ES2544713T3 (es) 2006-01-05 2015-09-03 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
AU2007227423B2 (en) 2006-03-20 2013-11-07 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
ES2318616T3 (es) * 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
GB0624689D0 (en) * 2006-12-11 2007-01-17 Glaxo Group Ltd Novel fluorescent kinase ligands and methods employing the same
WO2008110624A2 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano-Bicocca Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors
WO2008150010A1 (ja) * 2007-06-08 2008-12-11 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
JPWO2009011426A1 (ja) * 2007-07-19 2010-09-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｍｅｔを利用したスクリーニング方法
EP2192181A4 (de) * 2007-08-01 2010-12-08 Eisai R&D Man Co Ltd Screening-verfahren mit nutzung des neuen substrats c-ret für gamma-sekretase
ES2562077T3 (es) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
CA2926831A1 (en) * 2007-08-22 2009-02-26 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
WO2009064006A1 (ja) * 2007-11-15 2009-05-22 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA7を利用したスクリーニング方法
EP2223999B1 (de) * 2007-11-30 2017-10-18 Eisai R&D Management Co., Ltd. Epha4-polypeptid mit neuartiger aktivität und verwendung davon
US20100197688A1 (en) * 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
JP2011522872A (ja) * 2008-06-09 2011-08-04 オックスフォード ビオトヘラペウトイクス エルティーディー． エフリンａ型受容体７タンパク質
US20100256214A1 (en) * 2009-04-02 2010-10-07 Burnham Institute For Medical Research Eph receptor ligands and methods of use
WO2010141974A1 (en) * 2009-06-10 2010-12-16 The University Of Melbourne Therapeutic applications
US8159780B2 (en) 2009-07-15 2012-04-17 Seagate Technology Llc Recording head heater systems with two electrical connections
EP2483407A2 (de) 2009-09-30 2012-08-08 President and Fellows of Harvard College Verfahren zur autophagie-modulation durch modulation autophagie-verstärkender genprodukte
AU2011326032B2 (en) 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
JP2014500258A (ja) 2010-11-15 2014-01-09 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 制御放出粘膜付着システム
WO2012067839A2 (en) * 2010-11-15 2012-05-24 The J. David Gladstone Institutes Methods of treating neurodegenerative disease
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
CN104364390B (zh) 2011-10-14 2016-08-24 俄亥俄州立大学 与卵巢癌相关的方法和材料
WO2013090556A1 (en) 2011-12-13 2013-06-20 The Ohio State University Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
CN104685065B (zh) 2012-01-20 2017-02-22 俄亥俄州立大学 浸润性和预后的乳腺癌生物标志物标签
TW201716442A (zh) 2015-09-08 2017-05-16 衛材Ｒ＆Ｄ企管股份有限公司 抗EphA4抗體
CA3139398A1 (en) 2019-07-01 2021-01-07 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2023088483A1 (en) * 2021-11-22 2023-05-25 China Medical University Antibody specific to ephrin type-a receptor 10, chimeric antigen receptor t-cell expressing the same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
WO2003057165A2 (en) * 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
JP2005531609A (ja) * 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのシスインドリル−マレイミド誘導体
EP1553963A4 (de) * 2002-09-24 2006-05-03 Burnham Inst NEUE MITTEL ZUR MODULIERUNG DER EPH-REZEPTOR-AKTIVITûT

Also Published As

Publication number Publication date
EP1815255A1 (de) 2007-08-08
US20080213250A1 (en) 2008-09-04
DE602005014134D1 (de) 2009-06-04
CA2589173A1 (en) 2006-06-01
WO2006056467A1 (en) 2006-06-01
EP1815255B1 (de) 2009-04-22
EP1662259A1 (de) 2006-05-31

Similar Documents

Publication Publication Date Title
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005009748D1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
EA200971077A1 (ru) Гетероциклические модуляторы киназы
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
MX2010002674A (es) Moduladores de gamma secretasa.
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
MX2010006379A (es) Moduladores de la secretasa gamma.
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
NO20071272L (no) Modulatorer av muskarine reseptorer.
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
MX2010005028A (es) Moduladores de gamma secretasa.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE504600T1 (de) Verwendung von antikörpern gegen tweak zur behandlung von schlaganfall
EA200601267A1 (ru) Модуляторы рецепторов андрогена
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties